



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/574,786

04/06/2006

Stefan Golz

00497401108

8672

22907 7590 04/01/2008

BANNER & WITCOFF, LTD.

1100 13th STREET, N.W.

SUITE 1200

WASHINGTON, DC 20005-4051

EXAMINER

SAIDHA, TEKCHAND

ART UNIT

PAPER NUMBER

1652

MAIL DATE

DELIVERY MODE

04/01/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/574,786	Applicant(s) GOLZ ET AL.	
	Examiner Tekchand Saidha	Art Unit 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 April 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 and 21-23 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-18 and 21-23 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>6/28/2006</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Preliminary amendment files 4/6/2006 is acknowledged. Accordingly, claims 1-18 & 21-23 are present in this application.
2. Restriction is required under 35 U.S.C. 121 and 372.
3. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1 & 4-11, drawn to a method of screening for therapeutic agent useful in the treatment of a disease selected from the group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹, urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising the steps of

- i) contacting a test compound with a mosaic serine protease polypeptide, and
- ii) **detecting binding** of said test compound to said mosaic serine protease polypeptide.

Group II, claim(s) 2-3, drawn to a method of screening for therapeutic agent useful in the treatment of a disease selected from the group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹, urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising the steps of

- i) determining **activity** of a mosaic serine protease polypeptide at a certain concentration of a test compound or in the absence of said test compound, and
- ii) determining the activity of said polypeptide at a different concentration of said test compound.

Group III, claim(s) 12-17, drawn to a method of screening for therapeutic agent useful in the treatment of a disease selected from the

Art Unit: 1652

group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹, urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising the steps of

i) contacting a test compound with a mosaic serine protease **polynucleotide**, and

ii) **detecting binding** of said test compound to said mosaic serine protease polynucleotide.

Group IV, claim(s) 18, drawn to a method of diagnosing a disease selected from the group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹, urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising the steps of:

i) determining the amount of a mosaic serine protease polynucleotide in a sample taken from said mammal, and ii) determining the amount of mosaic serine protease polynucleotide in healthy and/or diseased mammals.

Group V, claim(s) 21, drawn to pharmaceutical composition for the treatment of disease selected from the group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹, urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising a therapeutic agent which regulates the activity of a serine protease polypeptide, wherein the therapeutic agent is-

- i) a small molecule,
- ii) an RNA molecule,
- iii) an antisense oligonucleotide,
- iv) a polypeptide,
- v) an antibody, or
- vi) a ribozyme

Group VI, claim(s) 22, drawn to pharmaceutical composition for the treatment of disease selected from the group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹,

Art Unit: 1652

urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising a mosaic serine protease **polynucleotide**.

Group VII, claim(s) 23, drawn to pharmaceutical composition for the treatment of disease selected from the group consisting of cardiovascular diseases¹, endocrinological diseases², metabolic diseases³, cancer⁴, inflammation⁵, gastroenterological diseases⁶, hematological diseases⁷, respiratory diseases⁸, neurological diseases⁹, urological diseases¹⁰ and reproduction disorders¹¹ in a mammal, comprising a mosaic serine protease **polypeptide**.

For each of inventions I-VII above, restriction to one of the diseases (1)-(11) is also required; and in case of Group V, a further election of one of the therapeutic agents (i)-(vi) is also required.

4. The inventions listed as Groups I-VII and (1)-(11) and in case of Group V, a further election of one of the therapeutic agents (i)-(vi) do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: The technical feature linking Groups I-VII and (1)-(11) appears to be that they all relate to mosaic serine protease. According to the international search report claims 1-26 lack novelty as being anticipated by Xiao et al. [WO 01/96538, 12/20/2001]. Therefore, Groups I-VII and (1)-(11) and/or (i)-(vi) share no special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art. Furthermore, the products of Groups V-VII and (1)-(11) and/or (i)-(vi) do not share a special common structural or functional feature while, the methods of Groups I-IV do not use the same reagents or produce the same results. Accordingly, Groups I-VII and (1)-(11) and/or (i)-(vi) are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

7. Brief description of drawing is missing and is required.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha whose telephone number is (571) 272 0940. The examiner can normally be reached on 8.30 am - 5.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nashaat Nashed can be reached on (571) 272 0934. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

Art Unit: 1652

USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Tekchand Saidha/

Primary Examiner, Art Unit 1652

Recombinant Enzymes, E02A65 Remsen Bld.

400 Dulany Street, Alexandria, VA

Telephone: (571) 272-0940

March 18, 2008